These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 2534253

  • 1. The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive.
    Upton GV, Corbin A.
    Yale J Biol Med; 1989; 62(5):445-57. PubMed ID: 2534253
    [Abstract] [Full Text] [Related]

  • 2. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
    London RS, Chapdelaine A, Upmalis D, Olson W, Smith J.
    Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
    [Abstract] [Full Text] [Related]

  • 3. SHBG, testosterone, androstenedione, 17-OH-Progesterone plasma levels in PCO affected women treated with a triphasic oral contraceptive.
    Negri P, Agnello G, Borghesani F, Tomain L, Minisci N, D'Errico G, Cavallini AR.
    Acta Eur Fertil; 1987; 18(6):375-80. PubMed ID: 3454501
    [Abstract] [Full Text] [Related]

  • 4. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A.
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [Abstract] [Full Text] [Related]

  • 5. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
    Anderson FD.
    Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552
    [Abstract] [Full Text] [Related]

  • 6. Effect of low-dose oral contraceptives on androgenic markers and acne.
    Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME.
    Contraception; 1999 Nov; 60(5):255-62. PubMed ID: 10717776
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL, Menard J, Rad M, Burggraaf J, de Kam ML, Tokay BA, Sivin I, Kluft C.
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [Abstract] [Full Text] [Related]

  • 8. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
    Lepot MR, Gaspard UJ.
    Int J Fertil; 1987 Jun; 32 Suppl():15-20. PubMed ID: 2906343
    [Abstract] [Full Text] [Related]

  • 9. An open study of Triphasil and Diane 50 in the treatment of acne.
    Wishart JM.
    Australas J Dermatol; 1991 Jun; 32(1):51-4. PubMed ID: 1834045
    [Abstract] [Full Text] [Related]

  • 10. Clinical evidence of the minimal androgenic activity of norgestimate.
    Chapdelaine A, Desmarais JL, Derman RJ.
    Int J Fertil; 1989 Jun; 34(5):347-52. PubMed ID: 2571595
    [Abstract] [Full Text] [Related]

  • 11. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
    Coenen CM, Thomas CM, Borm GF, Rolland R.
    Int J Fertil Menopausal Stud; 1995 Jun; 40 Suppl 2():92-7. PubMed ID: 8574256
    [Abstract] [Full Text] [Related]

  • 12. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
    Endrikat J, Blode H, Gerlinger C, Rosenbaum P, Kuhnz W.
    Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
    [Abstract] [Full Text] [Related]

  • 13. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A, De Leo V.
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [Abstract] [Full Text] [Related]

  • 14. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene].
    Belaisch J, Hommais-loufrani B.
    Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078
    [Abstract] [Full Text] [Related]

  • 15. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V.
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [Abstract] [Full Text] [Related]

  • 16. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
    Skouby SO, Endrikat J, Düsterberg B, Schmidt W, Gerlinger C, Wessel J, Goldstein H, Jespersen J.
    Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
    [Abstract] [Full Text] [Related]

  • 17. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives.
    Palatsi R, Hirvensalo E, Liukko P, Malmiharju T, Mattila L, Riihiluoma P, Ylöstalo P.
    Acta Derm Venereol; 1984 Feb; 64(6):517-23. PubMed ID: 6084924
    [Abstract] [Full Text] [Related]

  • 18. [Hypophyseal reaction state during oral contraceptiva (author's transl)].
    Gitsch E, Schneider WH, Schmid R, Spona J.
    Wien Klin Wochenschr; 1981 Oct 16; 93(19):599-601. PubMed ID: 6798764
    [Abstract] [Full Text] [Related]

  • 19. Antacid does not reduce the bioavailability of oral contraceptive steroids in women.
    Joshi JV, Sankolli GM, Shah RS, Joshi UM.
    Int J Clin Pharmacol Ther Toxicol; 1986 Apr 16; 24(4):192-5. PubMed ID: 3086241
    [Abstract] [Full Text] [Related]

  • 20. [Preclinical research and development of norethisterone].
    Mcguire JL, Hahn DW, Philipps A.
    Contracept Fertil Sex (Paris); 1985 Jan 16; 13(1 Suppl):437-44. PubMed ID: 12280212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.